Radioactive tracer could reveal breast Cancer's HER2 status without a needle
NCT ID NCT04277338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial tested a new radioactive tracer called 99mTc-HE3-G3 to see if it can safely and accurately detect HER2 protein in breast cancer tumors using SPECT imaging. Thirty adults with primary breast cancer received one injection of the tracer, followed by scans over 24 hours. The goal was to measure how the tracer spreads in the body and tumors, and to compare imaging results with standard biopsy tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m-labelled designed ankyrin repeat proteins HE3-G3 (99mTc-HE3-G3)
What this could lead to
If successful, this imaging method could help doctors see HER2 levels in breast cancer without needing a biopsy, guiding treatment decisions.
What could go wrong
This is an early Phase 1 trial with only 30 people. It focuses on safety and imaging, not treatment. The method may not be accurate enough for routine use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TomskNRMC
Tomsk, Russia